相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2022)
POS-335 COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS A TREATMENT FOR CHRONIC KIDNEY DISEASE: A HEALTH-ECONOMIC ANALYSIS OF DAPA-CKD
P. MCEWAN et al.
Kidney International Reports (2021)
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease
Peter Rossing et al.
DIABETES (2021)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Correction of anemia by dapagliflozin in patients with type 2 diabetes
Bergur V. Stefansson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
Daniel M. Sugrue et al.
PHARMACOECONOMICS (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Michael S. Kelly et al.
POSTGRADUATE MEDICINE (2019)
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
JingWei Li et al.
LANCET RHEUMATOLOGY (2019)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Heart failure in patients with kidney disease
Courtney Tuegel et al.
HEART (2017)
Effects of glycaemic management on diabetic kidney disease
Richard J. MacIsaac et al.
WORLD JOURNAL OF DIABETES (2017)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis
Nathan R. Hill et al.
PLOS ONE (2016)
Drug therapies to delay the progression of chronic kidney disease
Frank Ward et al.
CLINICAL MEDICINE (2015)
Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
Lana Pinto et al.
Diabetology & Metabolic Syndrome (2015)
Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment
Agneta A. Pagels et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
Hypertension in Cardiovascular and Kidney Disease
Joshua Botdorf et al.
CARDIORENAL MEDICINE (2011)
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
R. Bilous
DIABETIC MEDICINE (2008)
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease
AJ Palmer et al.
DIABETES CARE (2004)
Parametric survival models may be more accurate than Kaplan-Meier estimates
M May et al.
BRITISH MEDICAL JOURNAL (2003)
分享论文
